Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Senate Confirms Hahn as FDA Commissioner


 

"Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation's food supply." - Senator Lamar Alexander

Senate health committee Chairman Lamar Alexander (R-Tenn.) said that "Dr. Stephen Hahn's experience as a practicing oncologist, a successful leader of the MD Anderson Cancer Center and work at the National Institutes of Health (NIH) make him the right leader for the FDA at this critical time."

Dr. Hahn was confirmed by the Senate today by a bipartisan vote of 72-18 to serve as commissioner of the U.S. Food and Drug Administration (FDA).

"Dr. Hahn has extensive medical and research experience and is a proven leader in large health systems--all around, he is exactly the type of nominee we want to lead an agency as important as the FDA," Alexander said. "The Senate health committee I chair received sixteen letters of support for Dr. Hahn representing more than 80 organizations on behalf of doctors, patients, researchers, and from his colleagues. Dr. Hahn has also received support from five previous FDA commissioners, who served under Presidents Trump, Obama and Bush."

"Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation's food supply."

Alexander is chairman of the Senate health committee which has jurisdiction over confirmation of the FDA commissioner. Alexander chaired Dr. Hahn's confirmation hearing on November 20, and the committee approved his nomination on December 3 by a bipartisan vote of 18-5. Alexander today voted in favor of Dr. Hahn's nomination.

Dr. Hahn has previously served as the chief medical executive at the University of Texas MD Anderson Cancer Center in Houston. He is board certified in both medical oncology and radiation oncology, specializing over the course of his career on prostate, bladder, kidney, testicular, and lung cancers and sarcoma.


AACR Applauds Confirmation of Stephen M. Hahn, MD, as FDA Commissioner

Hahn has shown a commitment to science-directed and patient-focused policies

PHILADELPHIA -- The American Association for Cancer Research (AACR), the world's first and largest cancer research organization, commends the U.S. Senate for confirming Stephen M. Hahn to be the next commissioner of the U.S. Food and Drug Administration (FDA). Hahn was approved in the U.S. Senate on Thursday by a vote of 72-18.

"On behalf of the Board of Directors of the American Association for Cancer Research (AACR), and the 44,000 laboratory researchers, physician-scientists, other health care professionals, and patient advocates who constitute our national and international membership, I wish to extend our heartfelt congratulations to Dr. Hahn," said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. "The AACR is looking forward to working closely with him and his extraordinary team at the FDA to help facilitate and expedite the development and approval of safe and effective treatments for cancer patients."

Hahn has been a member of the AACR since 1999. He was an inaugural member of the AACR Radiation Science and Medicine Working Group Steering Committee and the AACR Radiation Oncology Task Force. Hahn is a member of the AACR Gertrude B. Elion Cancer Research Award Scientific Review Committee. He served in 2018 as cochair of the Workshop on Clinical Development of Drug-Radiotherapy Combinations held in partnership with the FDA, the AACR, and the American Society for Radiation Oncology (ASTRO).

"Dr. Hahn brings impressive qualifications to this extremely important position, including his background as a highly regarded physician and extremely effective scientific administrator," said AACR President Elaine R. Mardis, PhD, co-executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital. "Dr. Hahn understands the challenges that patients face every day, and also knows firsthand the importance of utilizing scientific-based evidence to evaluate the safety and efficacy of new therapies and devices."

Through its synergistic partnership with the FDA, the AACR has provided thought leadership, scientific guidance, and feedback to the FDA on a number of important scientific topics and initiatives, and the AACR looks forward to continuing this strong partnership under Commissioner Hahn.

 
Share:

Related Articles:


Recent Articles

Benefits of Fetal Surgery for Spina Bifida Continue Through School Age

Read More

Vanderbilt-led Team Discovers New Genetic Disease and Defines Underlying Mechanism

Zebrafish, pediatric patients and DNA biobank-linked electronic health records inform research study

Read More

AMA Issues Checklist for the Transition to E/M Office Visit Changes

The American Medical Association (AMA) is helping physician practices integrate fundamental changes to the coding and documentation of evaluation and management (E/M) office visit services that account for nearly $23 billion in Medicare spending.

Read More

AHA's Maryjane Wurth To Retire In 2020; Michelle Hood To Join The Association

Maryjane Wurth, the American Hospital Association's (AHA) executive vice president and chief operating officer (COO), will retire next year after a long and distinguished career in the hospital association field.

Read More

Tennessee Sees Fewer Infant Deaths In 2018

Infant Mortality Data Dashboard Now Available

Read More

Amedisys Expanding Commitment to End-of-Life Care for Veterans

Third Largest Hospice Provider Cared for 5,540 Dying Veterans Last Year

Read More

AMA Applauds Relief from Documentation Burden in New Medicare Rule

Many physicians will have reduced documentation beginning in 2021

Read More

Oncology Innovation in Nashville

From personalized medicine to innovation in GI care, Middle Tennessee oncology leaders share promising news.

Read More

Critical Insights into Nashville Health

For the first time in nearly two decades, Nashville has a countywide assessment providing insights into the health and well-being of the community.

Read More

Physician Spotlight: Leading with Compassion

Hospice care is so much more than simply pain management. Compassus CMO Dr. Kurt Merkelz focuses on helping patients live fully until the end.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: